Web Analytics
หุ้น BIIB (NASDAQ) | BIOGEN INC – วิเคราะห์โดย Deepscope
MARKET

Select Market Data Region

BIIB — BIOGEN INC (Healthcare >> Drug Manufacturers - General)

BIIB FAQ

What is BIIB's P/E ratio?

BIOGEN INC (BIIB) currently trades at a P/E ratio of 20.36.

What is BIIB's ROE?

BIOGEN INC reports a Return on Equity (ROE) of 7.36%.

What is BIIB's dividend yield?

BIOGEN INC offers a dividend yield of 0.00%.

What is BIIB's Deepscope Quality Score?

Deepscope rates BIIB's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy BIIB?

Deepscope's AI Timing Score for BIIB is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does BIIB belong to?

BIOGEN INC is classified under the Healthcare >> Drug Manufacturers - General sector on the NASDAQ exchange.

Stock Check   *ข้อมูลอัปเดตรายวัน ที่เวลา 09.30 น.*
(Price: 2026-06-04 | FS: 2026-03-31)

USD 196.45
0.49 (0.25%) Day Change
20.36
P/E
0.34
D/E
7.4%
ROE
4.7%
ROA
0.00%
Div Yield
-1.43
PEG
USD 196.45
Price
0.49 (0.25%)
Day Change
NEWS SCORE: 89

BIIB มีคุณภาพโดยรวมพอใช้ ( คะแนนปัจจัยพื้นฐาน = 62) และ จังหวะเข้าซื้อ ...(ล็อกอินเพื่อดู)...

62

QUALITY

Signal
NEUTRAL
Signal Description
Company financial health is OK
Reason
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ค่อนข้างต่ำ
อัตราเร่งของการเติบโตของอัตราผลตอบแทนผู้ถือหุ้น (ROE) ต่ำกว่าเกณฑ์
อัตราการเติบโตของอัตราผลตอบแทนผู้ถือหุ้น (ROE) ในปีก่อน เป็นลบ
อัตราเร่งของการเติบโตของอัตราผลตอบแทนสินทรัพย์ (ROA) ต่ำกว่าเกณฑ์
อัตราเร่งของการเติบโตของอัตรากำไรสุทธิ ต่ำกว่าเกณฑ์

88 Sign in

TIMING

Signal
OUTPERFORM
Signal Descri...
Good
Reason
Lorem ipsum dolor sit amet
Sign in to see timing analysis
Unlock timing signals and detailed reasons
Sign in free

ถ้าดูอย่างละเอียดจะพบว่า ปัจจัยทางคุณภาพ ไม่ดี สุขภาพทางการเงิน ยังไม่ดีนัก และ ประสิทธิภาพการทำกำไร พอใช้ , ...

ปัจจัยทางคุณภาพ 45%
X
X
X
X
  In Recommendations? Not in any sections
  Select Rate 0.00 From 30 days period
  Watch Rate 0.00 From 30 days period
  News Score 89
  Magic Formula Rank by ROA
1715
  Magic Formula Rank by ROE
1715
  Magic Formula Rank by ROIC
1737
  Price 196.45
  PBV / Sector
1.55 / 2.83
GOOD
  Earning Per Share 9.32
  PE / Sector
20.36 / 23.79
  PEG or PE/Growth / Sector
-1.43 / 0.07
  Average 1M Daily Value
202.88 M
GREAT
  Average 1W Daily Value
149.31 M
GREAT
ปัจจัยทางเทคนิค 57%
  MACD
  MACD Signal
  MACD Divergence
  RSI
  Stochastic Oscillator K
  Stochastic Oscillator D
  ADX
  Avg 5 day Timing Score
สุขภาพทางการเงิน 58%
X
X
X
X
  DE / Sector
  DE Average / Sector
  DE Change Average (%) / Sector
  Current Ratio / Sector
  Current Ratio Average / Sector
  Current Ratio Change Average (%) / Sector
  Quick Ratio / Sector
  Quick Ratio Average / Sector
  Quick Ratio Change Average (%) / Sector
  FCF/Share / Sector
  FCF/Share Average / Sector
  FCF/Share Change Average (%) / Sector
ประสิทธิภาพการทำกำไร 60%
X
X
X
X
X
X
X
  GPM (%) / Sector
  GPM Average (%) / Sector
  GPM Change Average (%) / Sector
  OPM (%) / Sector
  OPM Average (%) / Sector
  OPM Change Average (%) / Sector
  NPM (%) / Sector
13.92 / 18.17
  NPM Average (%) / Sector
17.15 / 17.77
GREAT
  NPM Change Average (%) / Sector
-8.48 / 93.90
  Asset Turnover / Sector
  Asset Turnover Average / Sector
  Asset Turnover Change Average (%) / Sector
  ROA (%) / Sector
4.65 / 8.90
  ROA Average (%) / Sector
6.32 / 8.60
  ROA Change Average (%) / Sector
-12.29 / 95.12
  ROE (%) / Sector
7.36 / 27.16
  ROE Average (%) / Sector
10.96 / 13.13
  ROE Change Average (%) / Sector
-16.16 / 97.95
  ROIC (%) / Sector
  ROIC Average (%) / Sector
  ROIC Change Average (%) / Sector
ผลตอบแทนต่อผู้ถือหุ้น 4%
X
  Dividend (%) / Sector
N/A / 2.60
  Dividend Average (%) / Sector
N/A / 3.43
  Dividend Change Average (%) / Sector
N/A / 2.29
รายละเอียดการจดทะเบียน
X
  Analyze Date 2026-06-05 09:12:40
  Symbol BIIB
  Name BIOGEN INC
  Sector Healthcare >> Drug Manufacturers - General
  Market NASDAQ
  Listed Shares 147.64 M
  Par Value N/A
  Calculated From Quarter
  Sign N/A
  Market Cap (M.USD) / Sector Average 28,930.97 / 233,824.82
ข่าว, ประมาณการ, ...
  Estimation Consensus See at WSJ.com
  Full details See at WSJ.com
  Chart See in Chart feature
  News See at Yahoo Finance

Address: 225 Binney Street, Cambridge, MA, United States, 02142

Phone: 617 679 2000

Website: https://www.biogen.com

Employees: 7,500

Sector: Healthcare >> Drug Manufacturers - General

Description: Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

ME vs SECTOR Healthcare >> Drug Manufacturers - General

BIIB (ME)
Sector Peers
Bubble size = Market Cap

Click a bubble to view stock details  ·  Bubble size represents market capitalization share

News

Smart picks. Just WOW stocks/funds/ETFs. No noise like other tools.
BIIB
BIIB
USD 196.45 (0.25%)
+ Watch + Port Chart